SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans
Authors:
Open Access
- 28 July 2021
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 70 (10) , 2364-2376
Abstract
SCO-267 is a full agonist of the free fatty acid receptor 1 (GPR40), which regulates the secretion of islet and gut hormones. In this phase 1 study, we aimed to evaluate the clinical profile of single and multiple once-daily oral administration of SCO-267 in healthy adults and patients with diabetes. Plasma SCO-267 concentration was seen to increase in a dose-dependent manner after administration, and its plasma exposure was maintained for 24 h. Repeated dose did not alter the pharmacokinetic profile of SCO-267 in healthy adults. SCO-267 was generally safe and well tolerated at all evaluated single and multiple doses. Single and repeated doses of SCO-267 stimulated the secretion of insulin, glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, and peptide YY in healthy adults. Furthermore, a single dose of SCO-267 stimulated the secretion of these hormones, decreased fasting hyperglycemia, and improved glycemic control during an oral glucose tolerance test in patients with diabetes, without inducing hypoglycemia. This study is the first to demonstrate the clinical effects of a GPR40 full agonist. SCO-267 is safe and well tolerated and exhibits once-daily oral dosing potential. Its robust therapeutic effects on hormonal secretion and glycemic control make SCO-267 an attractive drug candidate for the treatment of diabetes.Keywords
This publication has 29 references indexed in Scilit:
- Long‐term safety and efficacy of fasiglifam (TAK‐875), a G‐protein‐coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52‐week open‐label phase III studyDiabetes, Obesity and Metabolism, 2016
- Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food IntakeDiabetes, 2014
- Peptide YY: more than just an appetite regulatorDiabetologia, 2014
- Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 DiabetesDiabetes Care, 2013
- A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in RodentsPLOS ONE, 2012
- Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full AgonistACS Medicinal Chemistry Letters, 2012
- TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trialThe Lancet, 2012
- GPR40‐induced insulin secretion by the novel agonist TAK‐875: first clinical findings in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2011
- The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty AcidsJournal of Biological Chemistry, 2003
- Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40Nature, 2003